18 Jul 2014 07:00
NOTICE OF INTERIM RESULTS
LONDON, UK, 18 July, 2014 - Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, will announce its interim results for the six months ended 30 June 2014 on Thursday 21 August 2014. The results presentation and a webcast recording of the event will be available on the Company's website at www.skyepharma.com.
-Ends-
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer Andrew Derodra, Chief Financial Officer | +44 207 881 0524 |
| |
FTI Consulting | |
Julia Phillips/Natalie Garland-Collins | +44 203 727 1000 |
N+1 Singer | |
Shaun Dobson/Gillian Martin | +44 207 496 3000 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com